Lataa...
Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design
The approval of EGFR and ALK directed tyrosine kinase inhibitors materialized the concept of tailoring therapy on the basis of specific biomarkers for treating patients with NSCLC. Research for other biologics, although demonstrating clinical benefit, has been less successful so far for producing bi...
Tallennettuna:
| Julkaisussa: | J Pers Med |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4263964/ https://ncbi.nlm.nih.gov/pubmed/25563357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm4030386 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|